Specificity of the Substituted Benzimidazole B 823-08: A Prodrug for Gastric Proton Pump Inhibition

Pharmacology ◽  
1987 ◽  
Vol 34 (5) ◽  
pp. 269-278 ◽  
Author(s):  
W. Bohnenkamp ◽  
M. Eltze ◽  
K. Heintze ◽  
W. Kromer ◽  
R. Riedel ◽  
...  
Keyword(s):  
Proton Pump ◽  
Proton Pump Inhibition ◽  
Gastric Proton Pump

scholarly journals Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients

2017 ◽  
Vol 8 (1) ◽  
pp. e215 ◽  
Author(s):  
Edith Lahner ◽  
Cristina Brigatti ◽  
Ilaria Marzinotto ◽  
Marilia Carabotti ◽  
Giulia Scalese ◽  
...  
Keyword(s):  
Proton Pump ◽  
Gastric Proton Pump

A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate

2013 ◽  
Vol 48 (9) ◽  
pp. 1016-1022 ◽  
Author(s):  
Joongyub Lee ◽  
KyungEun Youn ◽  
Nam-Kyong Choi ◽  
Jin-Ho Lee ◽  
DongYoon Kang ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Proton Pump ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Proton Pump Inhibition ◽  
Control Study

scholarly journals Proton Pump Inhibition is a Feasible Primary Alternative to Surgery and Balloon Dilatation in Adult Peptic Pyloric Stenosis (APS): Report of Six Consecutive Cases

2006 ◽  
Vol 88 (2) ◽  
pp. 174-175 ◽  
Author(s):  
J Shabbir ◽  
S Durrani ◽  
PF Ridgway ◽  
K Mealy
Keyword(s):  
Peptic Ulcer ◽  
Peptic Ulcer Disease ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Pyloric Stenosis ◽  
Median Duration ◽  
Oral Treatment ◽  
Duration Of Symptoms ◽  
Ulcer Disease ◽  
Proton Pump Inhibition

INTRODUCTION Surgery has been the gold standard in the treatment of adult pyloric stenosis (APS). The introduction of proton pump inhibitors (PPIs) in 1989 revolutionised the treatment of peptic ulcer disease and its complications. PATIENTS AND METHODS We carried out a prospective study to evaluate the effectiveness of PPIs as an alternative to surgery for treatment of APS. Six consecutive patients admitted with a diagnosis of adult peptic pyloric stenosis between November 1999 and August 2002 were studied. The diagnosis was confirmed with endoscopy. All patients were commenced on a twice-daily dose of intravenous PPI. This was changed to oral treatment after 2 days. Main outcome measures evaluated were resolution of symptoms on PPIs and failure of medical therapy. RESULTS There were five females and one male. Median age at diagnosis was 72 years (range, 30–90 years). Median duration of symptoms was 2 weeks (range, 1–5 weeks). Of the patients, five had a history of peptic ulcer disease. Complete resolution was achieved in 5 patients (83%). Median duration for resolution of symptoms was 9 days (range, 5–14 days). All patients were changed to oral PPIs after 2 days. One patient did not respond to oral therapy and required surgical intervention (pyloroplasty). Median follow-up was 26 months (range, 6–48 months). There was no recurrence of symptoms. All patients were discharged on low-dose PPI. CONCLUSIONS This study supports the view that proton pump inhibitors are a safe and feasible alternative to surgery in adult pyloric stenosis secondary to peptic ulcer disease.

The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation

2019 ◽  
Vol 26 (3) ◽  
pp. e308-e313 ◽  
Author(s):  
Tomáš Bolek ◽  
Matej Samoš ◽  
Lucia Stančiaková ◽  
Jela Ivanková ◽  
Ingrid Škorňová ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Proton Pump ◽  
Proton Pump Inhibition ◽  
The Impact

Sites of resistance changes with inhibition of acid secretion in frog stomach

1986 ◽  
Vol 250 (5) ◽  
pp. G639-G647
Author(s):  
W. S. Rehm ◽  
G. Carrasquer ◽  
M. Schwartz
Keyword(s):  
Acid Secretion ◽  
Proton Pump ◽  
Tubular Cell ◽  
Secretory Rate ◽  
Tubular Cells ◽  
Resistance Increase ◽  
Frog Stomach ◽  
Scn Resistance ◽  
Gastric Proton Pump ◽  
Resistance Decrease

The primary purpose of this study was to determine the sites of resistance changes from thiocyanate inhibition of secretion to better evaluate models of the gastric proton pump. The potential difference, resistance, and H+ secretory rate were measured with various tonicities of the secretory fluid. Thiocyanate (SCN) inhibition generally produces a resistance increase, but with nutrient Ba, the resistance is high and SCN decreases it. The latter effect is also seen with cimetidine. In the secreting fundus a hypotonic secretory solution has a small effect on resistance, but in the inhibited fundus the effect is huge, due to increase of resistance of the lumen-tubular cell pathway. With a hypotonic secretory solution, for inhibited fundus (cimetidine or omeprazole) and antrum, SCN does not decrease the resistance of the surface cells and/or the transintercellular pathways with or without Ba. The SCN resistance decrease with Ba is via the tubular cell pathway. With Ba the resistance of the nutrient membrane of the tubular cells decreases after SCN or cimetidine inhibition. The findings further support the concept that under standard conditions the resistance via the lumina and tubular cells is low and that via the surface cells and transintercellular pathways is high.

scholarly journals Expression of ATP1AL1, a Non-Gastric Proton Pump, in Human Colorectum.

2002 ◽  
Vol 52 (3) ◽  
pp. 317-321 ◽  
Author(s):  
Yuji Takahashi ◽  
Hideki Sakai ◽  
Mutsuko Kuragari ◽  
Tomoyuki Suzuki ◽  
Katsunori Tauchi ◽  
...  
Keyword(s):  
Proton Pump ◽  
Gastric Proton Pump
Sign in / Sign up

Export Citation Format

Share Document